Search Result

Results for "

Ca2 /calmodulin

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Calcium Channel (7) Calmodulin (18) CaMK (23) Adenylate Cyclase (1) AMPK (2) Antibiotic (1) Apoptosis (11) Autophagy (11) Bacterial (2) Calcineurin (1) Cholinesterase (ChE) (2) Dopamine Receptor (2) EGFR (1) Endogenous Metabolite (1) Ferroptosis (1) Fungal (1) mGluR (2) Mitochondrial Metabolism (1) Myosin (3) Na+/K+ ATPase (1) NF-κB (1) NO Synthase (1) Parasite (1) Phosphatase (4) Phosphodiesterase (PDE) (9) PKA (1) PKC (6) Potassium Channel (3) PROTACs (1) Reference Standards (4) Ser/Thr Kinase (1) Src (1) Trk Receptor (1)
By Research Areas:	Cancer (11) Cardiovascular Disease (6) Infection (5) Inflammation/Immunology (12) Metabolic Disease (9) Neurological Disease (34)

By Targets:

Calcium Channel (7)

Calmodulin (18)

CaMK (23)

Adenylate Cyclase (1)

AMPK (2)

Antibiotic (1)

Apoptosis (11)

Autophagy (11)

Bacterial (2)

Calcineurin (1)

Cholinesterase (ChE) (2)

Dopamine Receptor (2)

EGFR (1)

Endogenous Metabolite (1)

Ferroptosis (1)

Fungal (1)

mGluR (2)

Mitochondrial Metabolism (1)

Myosin (3)

Na+/K+ ATPase (1)

NF-κB (1)

NO Synthase (1)

Parasite (1)

Phosphatase (4)

Phosphodiesterase (PDE) (9)

PKA (1)

PKC (6)

Potassium Channel (3)

PROTACs (1)

Reference Standards (4)

Ser/Thr Kinase (1)

Src (1)

Trk Receptor (1)

By Research Areas:

Cancer (11)

Cardiovascular Disease (6)

Infection (5)

Inflammation/Immunology (12)

Metabolic Disease (9)

Neurological Disease (34)

Inhibitors & Agonists

Peptides

Natural
Products

Antibodies

Targets Recommended: Calmodulin CaMK Calcium Channel CRAC Channel Na+/Ca2+ Exchanger CaSR

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-19805

STO-609 Maximum Cited Publications 31 Publications Verification	CaMK AMPK Autophagy	Metabolic Disease
STO-609 is a selective and cell-permeable inhibitor of the Ca ²⁺/calmodulin-dependent protein kinase kinase (CaM-KK), with K_i values of 80 and 15 ng/mL for recombinant CaM-KKα and CaM-KKβ, respectively. STO-609 inhibits AMP-activated protein kinase kinase (AMPKK) activity in HeLa cell lysates with an IC₅₀ ~0.02 g/ml.

HY-N6732

K-252a 25+ Cited Publications SF2370; Antibiotic K 252a; Antibiotic SF 2370	Autophagy PKA PKC Trk Receptor CaMK	Infection Inflammation/Immunology
K-252a, a staurosporine analog, inhibits protein kinase, with IC₅₀ values of 470 nM, 140 nM, 270 nM, and 1.7 nM for PKC, PKA, Ca ²⁺/calmodulin-dependent kinase type II, and phosphorylase kinase, respectively . K-252a is a potent inhibitor (IC₅₀ of 3 nM) of the tyrosine protein kinase (TRK) activity of the NGF receptor gp140trk, the product of the trk protooncogene .

HY-B1077

Penfluridol 5+ Cited Publications R-16341	Calcium Channel Dopamine Receptor Autophagy Apoptosis	Neurological Disease Inflammation/Immunology Cancer
Penfluridol (R-16341) is a potent, long-acting, first-generation, oral diphenylbutylpiperidine antipsychotic agent by targeting D2-like dopamine receptor. Penfluridol effectively inhibits TNFα-induced NF-κB activation and alleviates the severity of arthritis and colitis in vivo. Penfluridol is a Ca2+-calmodulin inhibitor. Penfluridol induces apoptosis and autophagy. Penfluridol is used for chronic schizophrenia, acute psychosis, Tourette syndrome and autoimmune diseases. Penfluridol inhibites the growth of E. faecalis planktonic cells with the MIC of 7.81 μg/ml .

HY-103319

Calmidazolium chloride 4 Publications Verification R 24571	Autophagy Calmodulin	Neurological Disease Cancer
Calmidazolium chloride (R 24571) is a *calmodulin* antagonist, antagonizing CaM-dependent phosphodiesterase and calmodulin-induced activation of erythrocyte Ca2+-transporting ATPase with IC₅₀s of 0.15 and 0.35 μM, respectively . Also in anti-cancer research . Calmidazolium binds to calmodulin with a K_d of 3 nM.

HY-100912

W-7 hydrochloride 5+ Cited Publications	Phosphodiesterase (PDE) Myosin Apoptosis Calmodulin Potassium Channel	Cancer
W-7 hydrochloride is a selective *calmodulin* antagonist. W-7 hydrochloride inhibits the *Ca ²⁺-calmodulin*-dependent phosphodiesterase and myosin light chain kinase with IC₅₀ values of 28 μM and 51 μM, respectively. W-7 hydrochloride induces apoptosis and has antitumor and vascular relaxing activity. W-7 hydrochloride is a blocker of Kv4.3 and can be used for research of arrhythmias .

HY-Z0478

(-)-Limonene 1 Publications Verification (S)-(-)-Limonene	Bacterial Antibiotic CaMK	Infection Cardiovascular Disease Metabolic Disease
(-)-Limonene ((S)-(-)-Limonene) is orally active and can cause mild bronchoconstriction. (-)-Limonene alleviates cytosolic and mitochondrial oxidative stress by inhibiting the increase of calcium ions (Ca ²⁺) and Ca ²⁺/calmodulin-dependent protein kinase II (CaMKII). It also exerts anti-stress effects by inhibiting the activity of the hypothalamic-pituitary-adrenal (HPA) axis. Additionally, (-)-Limonene can be used as an antibacterial agent in aquaculture .

HY-108599

DCP-LA 5+ Cited Publications FR236924	PKC CaMK Phosphatase Apoptosis	Neurological Disease
DCP-LA (FR236924), a linoleic acid derivative, selectively and directly activates PKCε. DCP-LA activates Ca( ²⁺)/calmodulin-dependent protein kinase II (CaMKII) and inhibits protein phosphatase-1 (PP-1) to stimulate AMPA receptor exocytosis. DCP-LA inhibits activation of caspase-3/-9 and protects neurons at least in part from oxidative stress-induced apoptosis .

HY-P1821

Myelin Basic Protein 2 Publications Verification MHP4-14	PKC	Neurological Disease
Myelin Basic Protein (MHP4-14), a synthetic peptide comprising residues 4-14 of myelin basic protein, is a very selective PKC substrate (K_m=7 μM). Myelin Basic Protein is not phosphorylated by cyclic AMP-dependent protein kinase, casein kinases I and II, Ca ²⁺/calmodulin-dependent protein kinase II, or phosphorylase kinase, and can be routinely used for the assay of protein kinase C with low background in the crude tissue extracts .

HY-115719

NR162	Ser/Thr Kinase	Neurological Disease
NR162 is a selective CASK (Ca ²⁺/calmodulin-dependent Ser/Thr kinase) inhibitor with an IC₅₀ of 80 nM and a Kd of 22 nM. NR162 shows about 50-fold selectivity for CASK than TYRO3. NR162 targets the unique GFG motif of CASK and has excellent shape complementarity to the CASK ATP binding pocket. NR162 can be used for the research of neurological diseases .

HY-105118A

Zaldaride maleate CGS-9343B; KW 5617	Calmodulin	Neurological Disease Metabolic Disease Inflammation/Immunology
Zaldaride maleate (CGS-9343B) is a potent, orally active and selective inhibitor of *calmodulin. Zaldaride maleate inhibits CaM (calmodulin)-stimulated cAMP phosphodiesterase activity, with an IC₅₀* of 3.3 nM . Zaldaride maleate prevents estrogen-induced transcription activation by ER, reversibly blocks voltage-activated Na ⁺, Ca ²⁺ and K ⁺ currents in PC12 cells and inhibits nAChR .

HY-110140

(E)-KN-93 phosphate	CaMK	Cardiovascular Disease Neurological Disease
(E)-KN-93 phosphate is a Ca ²⁺/calmodulin-dependent protein kinase II (CaMKII) inhibitor with IC₅₀ values of 9 μM and 3 μM against CaMKIIδ_Monomer and CaMKIIδ_Dodecamer, respectively. (E)-KN-93 phosphate can be used in research on epilepsy, depression, and arrhythmias. .

HY-P1077

CALP1 3 Publications Verification	mGluR Phosphodiesterase (PDE) Apoptosis Calmodulin	Inflammation/Immunology
CALP1 is a calmodulin (CaM) agonist (K_d of 88 µM) with binding to the CaM EF-hand/Ca ²⁺-binding site. CALP1 blocks calcium influx and apoptosis (IC₅₀ of 44.78 µM) through inhibition of calcium channel opening. CALP1 blocks glutamate receptor channels and blocks a store-operated nonselective cation channel. CALP1 activates CaM-dependent phosphodiesterase activity .

HY-W181102

NFAT Inhibitor-2	Calcineurin	Cardiovascular Disease Neurological Disease Inflammation/Immunology
NFAT Inhibitor-2 is a potent inhibitor of calcineurin NFAT signalling. Calcineurin is a serine/threonine protein phosphatase regulated by Ca2+ and calmodulin. NFAT Inhibitor-2 has the potential for the research of inflammatory disease, an autoimmune disorder, a cardiovascular disease, a neurodegenerative disease, a disease occurring with uncontrolled cell proliferation and/or differentiation, an angiogenesis-related disease, an allergy, anaphylaxis and alopecia (extracted from patent WO2016207212A1, compound 17) .

HY-P1075

CALP3 2 Publications Verification	Calcium Channel	Neurological Disease Cancer
CALP3, a Ca ²⁺-like peptide, is a potent Ca ²⁺ channel blocker that activates EF hand motifs of Ca ²⁺-binding proteins. CALP3 can functionally mimic increased [Ca ²⁺]_i by modulating the activity of Calmodulin (CaM), Ca ²⁺ channels and pumps. CALP3 has the potential in controlling apoptosis in diseases such as AIDS or neuronal loss due to ischemia .

HY-100779

Rimacalib SMP 114	CaMK Autophagy	Metabolic Disease
Rimacalib (SMP 114) is a Ca ²⁺/calmodulin-dependent protein kinase II (CaMKII) inhibitor, with IC₅₀s of ~1 μM for CaMKIIα to ~30 μM for CaMKIIγ .

HY-P1247

Calcineurin autoinhibitory peptide	Phosphatase	Neurological Disease
Calcineurin autoinhibitory peptide is a selective inhibitor of Ca ²⁺/calmodulin-dependent protein phosphatase (calcineurin), with an IC₅₀ of ~10 μM. Calcineurin autoinhibitory peptide could protect neurons from excitatory neuronal death .

HY-P1805

Calmodulin Binding Peptide 1	Calmodulin	Neurological Disease
Calmodulin Binding Peptide 1 is a high-affinity (pM) CaM-binding peptide derived from smooth muscle myosin light chain kinase (MLCK peptide). The interface of the complex formed by Calmodulin Binding Peptide 1 and Ca ²⁺-CaM can be specifically bound by small-molecule inhibitors, serving as a key target for selective regulation of smooth muscle contraction and development of anti-CaM drugs .

HY-P1077A

CALP1 TFA 3 Publications Verification	mGluR Phosphodiesterase (PDE) Apoptosis Calmodulin	Inflammation/Immunology
CALP1 TFA is a calmodulin (CaM) agonist (K_d of 88 µM) with binding to the CaM EF-hand/Ca ²⁺-binding site. CALP1 TFA blocks calcium influx and apoptosis (IC₅₀ of 44.78 µM) through inhibition of calcium channel opening. CALP1 TFA blocks glutamate receptor channels and blocks a store-operated nonselective cation channel. CALP1 TFA activates CaM-dependent phosphodiesterase activity .

HY-B1726

Phenacaine HoloCaine	Phosphodiesterase (PDE)	Metabolic Disease
Phenacaine (Holocaine) is a local agent that can suppress or relieve pain. Phenacaine inhibits the specific calmodulin-dependent stimulation of erythrocyte Ca ²⁺-ATPase and cyclic nucleotide phosphodiesterases from brain and heart .

HY-N1989

Bacoside A	Na+/K+ ATPase CaMK Apoptosis Cholinesterase (ChE) NO Synthase NF-κB	Neurological Disease Cancer
Bacoside A is an orally active, blood-brain barrier-permeable triterpenoid saponin that modulates the activities of ATPases, AChE, CaMK2A and iNOS. Derived from Bacopa monniera. Bacoside A exerts significant antioxidant, anti-inflammatory and anti-apoptotic effects by maintaining ion balance, scavenging reactive oxygen species, stabilizing cell membranes, and regulating the expression of NF-κB and apoptosis-related proteins. Bacoside A counteracts morphine-induced reductions in Na ⁺/K ⁺-ATPase, Ca ²⁺-ATPase and Mg ²⁺-ATPase activities, increases mitochondrial membrane potential, and decreases intracellular reactive oxygen species levels. Bacoside A specifically binds to calcium/calmodulin-dependent protein kinase IIA to trigger endoplasmic reticulum calcium release. Bacoside A exhibits non-apoptotic cytotoxicity against glioblastoma cells while protecting normal nerve cells from stress-induced damage. Bacoside A is applicable to the research of Parkinson's disease and glioblastoma multiforme .

HY-W170020

PTCA	CaMK	Metabolic Disease
PTCA is a potent Ca2+/calmodulin-dependent protein kinase II α (CaMKIIα) ligand with a pK_i value of 7.2 .

HY-P3811A

Autocamtide-3 acetate	CaMK	Neurological Disease
Autocamtide-3 acetate, a 13-amino-acid peptide containing Thr287, is a selective *CaMKII (Ca ²⁺/calmodulin-dependent* kinase II)** (CaMK) substrate .

HY-P0271A

Syntide 2 TFA 2 Publications Verification	CaMK	Neurological Disease
Syntide 2 (TFA), a *Ca ²⁺- and calmodulin* (CaM)-dependent protein kinase II (CaMKII) substrate peptide, selectively inhibits the gibberellin (GA) response, leaving constitutive and abscisic acid-regulated events unaffected .

HY-N10772

Albanin A	Calcium Channel Calmodulin Adenylate Cyclase	Neurological Disease Inflammation/Immunology
Albanin A, a flavonoid, suppresses glutamate release by decreasing Ca ²⁺/calmodulin/adenylate Cyclase 1 (AC1) activation in synaptosomes and exerts neuroprotective effect in vivo. Albanin A has anti-inflflammatory activity .

HY-130368

W-7 5+ Cited Publications	Calmodulin Potassium Channel Phosphodiesterase (PDE) Myosin Apoptosis	Cardiovascular Disease
W-7 is a selective *calmodulin* antagonist. W-7 inhibits the *Ca ²⁺-calmodulin*-dependent phosphodiesterase and myosin light chain kinase with IC₅₀ values of 28 μM and 51 μM, respectively. W-7 induces apoptosis and has antitumor and vascular relaxing activity. W-7 is a blocker of Kv4.3 and can be used for research of arrhythmias .

HY-P1076A

CALP2 TFA	Calmodulin	Inflammation/Immunology
CALP2 TFA is a calmodulin (CaM) antagonist (K_d of 7.9 µM) with high affinity for binding to the CaM EF-hand/Ca ²⁺-binding site. CALP2 TFA inhibits CaM-dependent phosphodiesterase activity and increases intracellular Ca ²⁺ concentrations. CALP2 TFA potently inhibits of adhesion and degranulation. CALP2 TFA is also a strong activator of alveolar macrophages .

HY-146268

CaMKIIα-IN-1	CaMK	Neurological Disease
CaMKIIα-IN-1 (Compound 4d) is an orally active Ca ²⁺/calmodulin-dependent protein kinase II α (CaMKIIα) inhibitor with a K_D of 219 nM for CaMKIIα WT hub. CaMKIIα-IN-1 has good metabolic stability .

HY-W013857

Lavendustin C	CaMK EGFR Src	Cancer
Lavendustin C is a potent Ca ²⁺ calmodulin-dependent kinase II (CaMK II) inhibitor with an IC₅₀ of 0.2 µM. Lavendustin C inhibits EGFR-associated tyrosine kinase (IC₅₀=0.012 µM) and pp60 ^c-src(+) kinase (IC₅₀=0.5 µM) .

HY-P1821A

Myelin basic protein (4-14) TFA 2 Publications Verification MHP4-14 TFA	PKC	Neurological Disease
Myelin Basic Protein (MHP4-14) TFA, a synthetic peptide comprising residues 4-14 of myelin basic protein, is a very selective PKC substrate (K_m=7 μM). Myelin Basic Protein TFA is not phosphorylated by cyclic AMP-dependent protein kinase, casein kinases I and II, Ca ²⁺/calmodulin-dependent protein kinase II, or phosphorylase kinase, and can be routinely used for the assay of protein kinase C with low background in the crude tissue extracts .

HY-P1479

Calmodulin-Dependent Protein Kinase II (290-309)	Autophagy CaMK	Neurological Disease
Calmodulin-Dependent Protein Kinase II (290-309) is a potent CaMK antagonist with an IC₅₀ of 52 nM for inhibition of Ca2+/calmodulin-dependent protein kinase II .

HY-19805A

STO-609 acetate	CaMK AMPK Autophagy	Metabolic Disease
STO-609 acetate is a selective and cell-permeable inhibitor of the Ca ²⁺/calmodulin-dependent protein kinase kinase (CaM-KK), with K_i values of 80 and 15 ng/mL for recombinant CaM-KKα and CaM-KKβ, respectively. STO-609 acetate inhibits AMP-activated protein kinase kinase (AMPKK) activity in HeLa cell lysates with an IC₅₀ ~0.02 g/ml.

HY-P1479A

Calmodulin-Dependent Protein Kinase II(290-309) acetate	Autophagy CaMK	Neurological Disease
Calmodulin-Dependent Protein Kinase II (290-309) acetate is a potent CaMK antagonist with an IC₅₀ of 52 nM for inhibition of Ca2+/calmodulin-dependent protein kinase II .

HY-115745

Calmodulin antagonist-1	Calmodulin	Cardiovascular Disease
Calmodulin antagonist-1 (A-5) is a calmodulin (CaM) antagonist. Calmodulin antagonist-1 inhibits calmodulin-activated Ca ²⁺-phosphodiesterase (PDE) (IC₅₀=66 μM). Calmodulin antagonist-1 also inhibits trypsin-treated Ca ²⁺-PDE (IC₅₀=560 μM) in a competitive fashion with respect to cyclic GMP .

HY-19025

CV-159	Calmodulin	Inflammation/Immunology
CV-159 is a unique dihydropyridine *Ca ²⁺* antagonist with an anti-calmodulin (CaM) action, and has antiinflammatory activities.

HY-P0271

Syntide 2	CaMK Autophagy	Neurological Disease
Syntide 2, a *Ca ²⁺- and calmodulin* (CaM)-dependent protein kinase II (CaMKII) substrate peptide, selectively inhibits the gibberellin (GA) response, leaving constitutive and abscisic acid-regulated events unaffected .

HY-P10316

CaMKI(299-320) Calmodulin-Dependent Protein Kinase I (299-320) Binding Domain	CaMK	Others
CaMKI (299-320) refers to a peptide consisting of residues 299-320 of Calcium/calmodulin-dependent protein kinase I (CaMKI). CaMKI (299-320), as a protein kinase, has a high affinity interaction with Ca ²⁺-CAM (K_d≤1 nM≤1 nM), which can phosphorylate specific substrate proteins, thereby regulating their activity. CaMKI (299-320) contains the CAM-binding domain and the self-inhibition domain, and CaMKI (299-320) can be used to study cell physiological processes, including cell proliferation, differentiation, and apoptosis .

HY-B1077R

Penfluridol (Standard) R-16341 (Standard)	Reference Standards Calcium Channel Dopamine Receptor Autophagy Apoptosis	Neurological Disease Inflammation/Immunology Cancer
Penfluridol (Standard) is the analytical standard of Penfluridol. This product is intended for research and analytical applications. Penfluridol (R-16341) is a potent, long-acting, first-generation, oral diphenylbutylpiperidine antipsychotic agent by targeting D2-like dopamine receptor. Penfluridol effectively inhibits TNFα-induced NF-κB activation and alleviates the severity of arthritis and colitis in vivo. Penfluridol is a Ca2+-calmodulin inhibitor. Penfluridol induces apoptosis and autophagy. Penfluridol is used for chronic schizophrenia, acute psychosis, Tourette syndrome and autoimmune diseases. Penfluridol inhibites the growth of E. faecalis planktonic cells with the MIC of 7.81 μg/ml .

HY-156104

CaMKIIα-PHOTAC	PROTACs CaMK	Neurological Disease
CaMKIIα-PHOTAC is a photochemically targeted chimera (PHOTAC) targeting Ca2+/calmodulin-dependent protein kinase II α (CaMKIIα). Molecules such as PHOTAC can catalyze the ubiquitination and degradation of target proteins through the endogenous proteasome under specific wavelengths of light. CaMKIIα-PHOTAC reduces synaptic function under light conditions, and it attenuates the intensity of evoked field excitatory postsynaptic potentials in the mouse hippocampus in response to physiological stimuli. CaMKIIα-PHOTAC plays a critical role in maintaining long-term potentiation and memory capacity in subcellular dendritic domains .

HY-P3944

Calmodulin Dependent Protein Kinase Substrate	CaMK	Neurological Disease
Calmodulin Dependent Protein Kinase Substrate is a *Ca ²⁺- and calmodulin* (CaM)-dependent protein kinase (CaMK) substrate peptide. Calmodulin Dependent Protein Kinase Substrate is a synthetic peptide substrate for protein kinases .

HY-P3943

Calmodulin Dependent Protein Kinase Substrate Analog	CaMK	Neurological Disease
Calmodulin Dependent Protein Kinase Substrate Analog is a *Ca ²⁺- and calmodulin* (CaM)-dependent protein kinase (CaMK) substrate peptide. Calmodulin Dependent Protein Kinase Substrate Analog is a synthetic peptide substrate for protein kinases .

HY-P2471

Neurogranin (48-76), mouse	Calmodulin	Neurological Disease
Neurogranin (48-76), mouse is a peptide corresponding to residues 48-76 of Neurogranin. Neurogranin, a calmodulin-binding protein, is exclusively expressed in the post-synapse, and mediates NMDAR driven synaptic plasticity by regulating the calcium-calmodulin (Ca ²⁺-CaM) pathway .

HY-124176

L-6355	Phosphodiesterase (PDE) Calmodulin	Cardiovascular Disease
L-6355 is an Amiodarone (HY-14187) related compound, which inhibits Ca ²⁺/calmodulin activated cyclic nucleotide phosphodiesterase with an IC₅₀ value of 0.65 μM. L-6355 is promising for research of antiarrhythmic and antianginal agent .

HY-P3811

Autocamtide-3	CaMK	Neurological Disease
Autocamtide-3, a 13-amino-acid peptide containing Thr287, is a selective *CaMKII (Ca ²⁺/calmodulin-dependent* kinase II)** (CaMK) substrate .

HY-E70813

CAMKK2 Recombinant Human Active Protein Kinase	CaMK	Neurological Disease
CaMKK2 is a serine/threonine protein kinase and the central component of a Ca ²⁺-calmodulin activated signalling pathway. CaMKK2 is highly enriched in brain neurons and regulates energy metabolism and neuronal processes. CAMKK2 Recombinant Human Active Protein Kinase is obtained by expressing CAMKK2 proteins .

HY-P1075A

CALP3 TFA	Calcium Channel	Neurological Disease Cancer
CALP3 TFA, a Ca ²⁺-like peptide, is a potent Ca ²⁺ channel blocker that activates EF hand motifs of Ca ²⁺-binding proteins. CALP3 TFA can functionally mimic increased [Ca ²⁺]_i by modulating the activity of Calmodulin (CaM), Ca ²⁺ channels and pumps. CALP3 TFA has the potential in controlling apoptosis in diseases such as AIDS or neuronal loss due to ischemia .

HY-142087

Beauverolide Ja	Calmodulin Endogenous Metabolite	Neurological Disease
Beauverolide Ja, a cyclotetradepsipeptide, is a potent calmodulin (CaM) inhibitor with a K_d of 0.078 μM and a K_i of 0.39 μM for Ca ²⁺-CaM. Beauverolide Ja is a secondary metabolite of Isaria fumosorosea .

HY-105118

Zaldaride CGS-9343B free base; KW 5617 free base	Calmodulin	Neurological Disease Metabolic Disease Inflammation/Immunology
Zaldaride (CGS-9343B free base) is a potent, orally active and selective inhibitor of *calmodulin. Zaldaride inhibits CaM (calmodulin)-stimulated cAMP phosphodiesterase activity, with an IC₅₀* of 3.3 nM . Zaldaride prevents estrogen-induced transcription activation by ER, reversibly blocks voltage-activated Na ⁺, Ca ²⁺ and K ⁺ currents in PC12 cells and inhibits nAChR .

HY-103319R

Calmidazolium chloride (Standard) R 24571 (Standard)	Reference Standards Autophagy Calmodulin	Neurological Disease Cancer
Calmidazolium chloride (Standard) is the analytical standard of Calmidazolium chloride (HY-103319). This product is intended for research and analytical applications. Calmidazolium chloride (R 24571) is a calmodulin antagonist, antagonizing CaM-dependent phosphodiesterase and calmodulin-induced activation of erythrocyte Ca2+-transporting ATPase with IC₅₀s of 0.15 and 0.35 μM, respectively . Also in anti-cancer research . Calmidazolium binds to calmodulin with a K_d of 3 nM.

HY-P1247A

Calcineurin autoinhibitory peptide TFA	Phosphatase	Neurological Disease
Calcineurin autoinhibitory peptide TFA is a selective inhibitor of Ca ²⁺/calmodulin-dependent protein phosphatase (calcineurin), with an IC₅₀ of ~10 μM. Calcineurin autoinhibitory peptide TFA could protect neurons from excitatory neuronal death .

HY-P1076

CALP2	Calmodulin	Inflammation/Immunology
CALP2 is a calmodulin (CaM) antagonist ( (K_d of 7.9 µM)) with high affinity for binding to the CaM EF-hand/Ca ²⁺-binding site. CALP2 inhibits CaM-dependent phosphodiesterase activity and increases intracellular Ca ²⁺ concentrations. CALP2 potently inhibits of adhesion and degranulation. CALP2 is also a strong activator of alveolar macrophages .

Cat. No.	Product Name	Target	Research Area